Literature DB >> 8630923

The results of a five-year early prostate cancer detection intervention. Investigators of the American Cancer Society National Prostate Cancer Detection Project.

C Mettlin1, G P Murphy, R J Babaian, A Chesley, R A Kane, P J Littrup, F K Mostofi, P S Ray, A M Shanberg, A Toi.   

Abstract

BACKGROUND: The American Cancer Society-National Prostate Cancer Detection Project (ACS-NPCDP) is a multidisciplinary evaluation of early prostate cancer detection interventions. This report summarizes the experience of the investigators to date and describes the overall and relative performance of the different detection modalities studied in this project.
METHODS: Two thousand nine hundred ninety-nine men aged 55 to 70 years at entry who were not already under evaluation for prostate cancer were recruited to participate in up to 5 annual examinations by prostate specific antigen (PSA), digital rectal examination (DRE), and transrectal ultrasound (TRUS). In the course of 5 years of intervention, ACS-NPCDP investigators have completed 9937 examinations, recommended 1215 biopsies, and detected 203 cancers.
RESULTS: Loss to cohort follow-up was greatest in the first year. Overall, TRUS led to twice the number of recommendations for biopsy compared with DRE (8.9% versus 4.4%). Elevated PSA was observed in 13.0% of 9535 measurements performed. The overall cancer detection rate declined significantly during the five years of intervention. Detection was significantly associated with age and symptom status at entry. DRE had lower sensitivity compared with TRUS or PSA, particularly in later years of follow-up. The specificity of TRUS was lower than that for DRE. PSA was elevated in 69.2% of examinations that led to cancer detection, compared with only 10.9% when cancer was not found. PSA level, PSA density, and PSA change were all related to the presence of cancer. Less than 6% of the cancers detected in this study were clinically advanced at the time of diagnosis.
CONCLUSIONS: These data quantify the yield of early cancer detection that may be expected when PSA, DRE, and TRUS are used in populations comparable to the men participating in the ACS-NPCDP. Continued follow-up and further research is needed to assess whether men receiving early prostate cancer interventions benefit as a result.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8630923     DOI: 10.1002/(SICI)1097-0142(19960101)77:1<150::AID-CNCR25>3.0.CO;2-3

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  19 in total

1.  Knowledge, attitudes, and screening practices among older men regarding prostate cancer.

Authors:  C B Steele; D S Miller; C Maylahn; R J Uhler; C T Baker
Journal:  Am J Public Health       Date:  2000-10       Impact factor: 9.308

2.  At risk or not at risk? A meta-analysis of the prognostic accuracy of psychometric interviews for psychosis prediction.

Authors:  Paolo Fusar-Poli; Marco Cappucciati; Grazia Rutigliano; Frauke Schultze-Lutter; Ilaria Bonoldi; Stefan Borgwardt; Anita Riecher-Rössler; Jean Addington; Diana Perkins; Scott W Woods; Thomas H McGlashan; Jimmy Lee; Joachim Klosterkötter; Alison R Yung; Philip McGuire
Journal:  World Psychiatry       Date:  2015-10       Impact factor: 49.548

3.  Prostate mechanical imaging: 3-D image composition and feature calculations.

Authors:  Vladimir Egorov; Suren Ayrapetyan; Armen P Sarvazyan
Journal:  IEEE Trans Med Imaging       Date:  2006-10       Impact factor: 10.048

Review 4.  Optimal cost-effective staging evaluations in prostate cancer.

Authors:  Gregory L Lacy; Douglas W Soderdahl; Javier Hernandez
Journal:  Curr Urol Rep       Date:  2007-05       Impact factor: 3.092

5.  Current and projected annual direct costs of screening asymptomatic men for prostate cancer using prostate-specific antigen.

Authors:  M D Krahn; A Coombs; I G Levy
Journal:  CMAJ       Date:  1999-01-12       Impact factor: 8.262

6.  Shear wave dispersion ultrasonic vibrometry for measuring prostate shear stiffness and viscosity: an in vitro pilot study.

Authors:  F G Mitri; M W Urban; M Fatemi; J F Greenleaf
Journal:  IEEE Trans Biomed Eng       Date:  2010-06-28       Impact factor: 4.538

7.  Transrectal ultrasound guided biopsy of the prostate: random sextant versus biopsies of sono-morphologically suspicious lesions.

Authors:  Tillmann Loch; Ursula Eppelmann; Jan Lehmann; Bernd Wullich; Annemie Loch; Michael Stöckle
Journal:  World J Urol       Date:  2004-12-01       Impact factor: 4.226

8.  Methods for Assessing Improvement in Specificity when a Biomarker is Combined with a Standard Screening Test.

Authors:  Pamela A Shaw; Margaret S Pepe; Todd A Alonzo; Ruth Etzioni
Journal:  Stat Biopharm Res       Date:  2009-02-01       Impact factor: 1.452

Review 9.  Diagnostic strategies and the incidence of prostate cancer: reasons for the low reported incidence of prostate cancer in China.

Authors:  Ling Zhang; Shan Wu; Li-Rong Guo; Xue-Jian Zhao
Journal:  Asian J Androl       Date:  2008-12-01       Impact factor: 3.285

10.  The development of a web- and a print-based decision aid for prostate cancer screening.

Authors:  Caroline S Dorfman; Randi M Williams; Elisabeth C Kassan; Sara N Red; David L Dawson; William Tuong; Elizabeth R Parker; Janet Ohene-Frempong; Kimberly M Davis; Alexander H Krist; Steven H Woolf; Marc D Schwartz; Mary B Fishman; Carmella Cole; Kathryn L Taylor
Journal:  BMC Med Inform Decis Mak       Date:  2010-03-03       Impact factor: 2.796

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.